Na Li, Chengkun Xiao, Shushu Han, Minjie Lu, Qianxin Chen, Yuanzhong Yang, Luying Tang, Zefang Ren, Lin Xu
{"title":"EEF1G在乳腺癌中依赖bmi的预后作用：广州乳腺癌队列研究的15年随访","authors":"Na Li, Chengkun Xiao, Shushu Han, Minjie Lu, Qianxin Chen, Yuanzhong Yang, Luying Tang, Zefang Ren, Lin Xu","doi":"10.1002/cam4.70227","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Eukaryotic elongation factor 1 gamma (EEF1G) has emerged as a potential prognostic marker in various malignancies. Yet, its association with breast cancer (BC) prognosis, particularly in the context of body mass index (BMI) status, remains unexplored. Therefore, we investigated the prognostic value and role of EEF1G in BC across different BMI categories.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>EEF1G expression was assessed through immunohistochemistry in tissue microarrays on 1011 patients with primary invasive BC. Prognostic effects were analyzed using the Cox proportional hazards regression. GSE78958 dataset downloaded from the Gene Expression Omnibus (GEO) database was used to validate our findings. Gene Set Enrichment Analysis (GSEA) was performed using R packages, and protein–protein interaction (PPI) networks were generated using the STRING database and Cytoscape software.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Elevated EEF1G expression was associated with a better prognosis in patients with BMI ≤ 24 kg/m<sup>2</sup> (hazard ratio (HR) for overall mortality = 0.67, 95% confidence interval (CI): 0.43–1.03; HR for progression = 0.60, 95% CI: 0.42–0.86). In contrast, for patients with BMI > 24 kg/m<sup>2</sup>, it appeared to be associated with poorer outcomes (HR for overall mortality = 1.74, 95% CI: 0.96–3.17; HR for progression = 1.63, 95% CI: 1.00–2.66). In patients with BMI > 24 kg/m<sup>2</sup>, EEF1G was associated with specific metabolic and oncogenic pathways, which were not statistically significant in patients with BMI ≤ 24 kg/m<sup>2</sup>. The top interacting genes with <i>EEF1G</i> differed between the BMI categories.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study showed EEF1G expression was inversely associated with BC prognosis in different BMI categories, indicating its potential as a prognostic marker and therapeutic target in BC. The differential effects underscore the need for personalized approaches in BC management and research.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 17","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70227","citationCount":"0","resultStr":"{\"title\":\"BMI-dependent prognostic role of EEF1G in breast cancer: A 15-year follow-up of the Guangzhou Breast Cancer Cohort Study\",\"authors\":\"Na Li, Chengkun Xiao, Shushu Han, Minjie Lu, Qianxin Chen, Yuanzhong Yang, Luying Tang, Zefang Ren, Lin Xu\",\"doi\":\"10.1002/cam4.70227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Eukaryotic elongation factor 1 gamma (EEF1G) has emerged as a potential prognostic marker in various malignancies. Yet, its association with breast cancer (BC) prognosis, particularly in the context of body mass index (BMI) status, remains unexplored. Therefore, we investigated the prognostic value and role of EEF1G in BC across different BMI categories.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>EEF1G expression was assessed through immunohistochemistry in tissue microarrays on 1011 patients with primary invasive BC. Prognostic effects were analyzed using the Cox proportional hazards regression. GSE78958 dataset downloaded from the Gene Expression Omnibus (GEO) database was used to validate our findings. Gene Set Enrichment Analysis (GSEA) was performed using R packages, and protein–protein interaction (PPI) networks were generated using the STRING database and Cytoscape software.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Elevated EEF1G expression was associated with a better prognosis in patients with BMI ≤ 24 kg/m<sup>2</sup> (hazard ratio (HR) for overall mortality = 0.67, 95% confidence interval (CI): 0.43–1.03; HR for progression = 0.60, 95% CI: 0.42–0.86). In contrast, for patients with BMI > 24 kg/m<sup>2</sup>, it appeared to be associated with poorer outcomes (HR for overall mortality = 1.74, 95% CI: 0.96–3.17; HR for progression = 1.63, 95% CI: 1.00–2.66). In patients with BMI > 24 kg/m<sup>2</sup>, EEF1G was associated with specific metabolic and oncogenic pathways, which were not statistically significant in patients with BMI ≤ 24 kg/m<sup>2</sup>. The top interacting genes with <i>EEF1G</i> differed between the BMI categories.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This study showed EEF1G expression was inversely associated with BC prognosis in different BMI categories, indicating its potential as a prognostic marker and therapeutic target in BC. The differential effects underscore the need for personalized approaches in BC management and research.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 17\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70227\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70227\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70227","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
BMI-dependent prognostic role of EEF1G in breast cancer: A 15-year follow-up of the Guangzhou Breast Cancer Cohort Study
Objective
Eukaryotic elongation factor 1 gamma (EEF1G) has emerged as a potential prognostic marker in various malignancies. Yet, its association with breast cancer (BC) prognosis, particularly in the context of body mass index (BMI) status, remains unexplored. Therefore, we investigated the prognostic value and role of EEF1G in BC across different BMI categories.
Methods
EEF1G expression was assessed through immunohistochemistry in tissue microarrays on 1011 patients with primary invasive BC. Prognostic effects were analyzed using the Cox proportional hazards regression. GSE78958 dataset downloaded from the Gene Expression Omnibus (GEO) database was used to validate our findings. Gene Set Enrichment Analysis (GSEA) was performed using R packages, and protein–protein interaction (PPI) networks were generated using the STRING database and Cytoscape software.
Results
Elevated EEF1G expression was associated with a better prognosis in patients with BMI ≤ 24 kg/m2 (hazard ratio (HR) for overall mortality = 0.67, 95% confidence interval (CI): 0.43–1.03; HR for progression = 0.60, 95% CI: 0.42–0.86). In contrast, for patients with BMI > 24 kg/m2, it appeared to be associated with poorer outcomes (HR for overall mortality = 1.74, 95% CI: 0.96–3.17; HR for progression = 1.63, 95% CI: 1.00–2.66). In patients with BMI > 24 kg/m2, EEF1G was associated with specific metabolic and oncogenic pathways, which were not statistically significant in patients with BMI ≤ 24 kg/m2. The top interacting genes with EEF1G differed between the BMI categories.
Conclusions
This study showed EEF1G expression was inversely associated with BC prognosis in different BMI categories, indicating its potential as a prognostic marker and therapeutic target in BC. The differential effects underscore the need for personalized approaches in BC management and research.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
